For more than a decade, policymakers have promoted value-based care as the future of American healthcare. Pay for outcomes. Reward quality over volume.Lower costs while improving patient care. On paper, it makes sense. In theory, it aligns incentives. In practice? The results are more complicated. If we’re serious about healthcare reform, we need to ask a straightforward question: Is value-based care actually delivering measurable results, or are we just relabeling the

Everyone agrees the healthcare system needs to change. But almost no one agrees on how to change it. And even when they do? It takes forever.

Most people think of philanthropy as charity. I think of it as an investment, with an expected return measured in discoveries, not dollars. At the JKTG Foundation, we don’t fund cancer research the traditional way. We don’t issue massive RFPs or wait for consensus to form. We move quickly, prioritize bold thinkers, and stay close to the science. Why? Because the diseases we’re up against, like breast cancer, won’t wait.

That’s what happened with a recent study the JKTG Foundation supported, one that explored how iron-based nanoparticles could help detect and treat tumors more safely. This wasn’t hype. It was smart, specific science. And it’s the kind of work we’re proud to back.

You don’t usually associate spreadsheets with survival rates. But that’s exactly the connection Dr. Paul Macklin is exploring in our latest Driving Research episode.

When most people think about the cost of healthcare, they look at billing, drug prices, or insurance premiums. What they don’t see is the hidden cost that providers shoulder to comply with the rules. Every regulation comes with a price, not just in dollars, but also in terms of time, infrastructure, staffing, and attention. And when policymakers underestimate that cost, it distorts everything from reimbursement to patient access...